Objectives: Ceftaroline is an important therapeutic option for community-acquired pneumonia (CAP). Antimicrobial susceptibility to ceftaroline and other antimicrobial agents against Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae isolates collected worldwide from identified respi-ratory tract sources is reported by age groups (0-18, 19-65, and > 65 years).Methods: Antimicrobial susceptibility of isolates, collected as part of the ATLAS program (2017-2019), was performed per EUCAST/CLSI guidelines.Results: S. aureus ( N = 7103; methicillin-susceptible S. aureus [MSSA] = 4203; methicillin-resistant S. aureus [MRSA] = 2791), S. pneumoniae ( N = 4823; EUCAST/CLSI, penicillin-intermediate S. pneumoniae [PISP] = 1408/870; penicillin-resistant S. pneumoniae [PRSP] = 455/993), and H. influenzae ( N = 3850; BB- lactamase [ BBL]-negative = 3097; BBL-positive = 753) isolates were collected from respiratory tract speci-mens. Susceptibility to ceftaroline was 89.08%-97.83% for S. aureus, 99.95%-100% for MSSA, and 78.07%- 92.74% for MRSA isolates across age groups; S. aureus as well as MRSA isolates derived from the 0-18 years age group demonstrated the highest susceptibility rates to ceftaroline. Susceptibility to ceftaro-line was 98.25%-99.77% for S. pneumoniae, 99.74%-10 0% for PISP, and 86.23%-99.04% for PRSP isolates across age groups. Across all age groups, susceptibility to ceftaroline was 89.53%-99.70% for H. influenzae, 93.02%-10 0% for BBL-negative, and 77.78%-98.35% for BBL-positive isolates.Conclusion: Irrespective of age, susceptibility to ceftaroline was high among the majority of S. aureus, S. pneumoniae, and H. influenzae isolates collected in this study. & COPY; 2023 The Pfizer Inc and The Author(s). Published by Elsevier Ltd. On behalf of International Society for Chemotherapy of Infection and Cancer. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017-2019 / Utt, Eric; Kantecki, Michal; Cabezas-Camarero, Guillermo; Esposito, Susanna. - In: JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE. - ISSN 2213-7165. - 33:(2023), pp. 360-367. [10.1016/j.jgar.2023.05.002]
Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017-2019
Esposito, Susanna
2023-01-01
Abstract
Objectives: Ceftaroline is an important therapeutic option for community-acquired pneumonia (CAP). Antimicrobial susceptibility to ceftaroline and other antimicrobial agents against Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae isolates collected worldwide from identified respi-ratory tract sources is reported by age groups (0-18, 19-65, and > 65 years).Methods: Antimicrobial susceptibility of isolates, collected as part of the ATLAS program (2017-2019), was performed per EUCAST/CLSI guidelines.Results: S. aureus ( N = 7103; methicillin-susceptible S. aureus [MSSA] = 4203; methicillin-resistant S. aureus [MRSA] = 2791), S. pneumoniae ( N = 4823; EUCAST/CLSI, penicillin-intermediate S. pneumoniae [PISP] = 1408/870; penicillin-resistant S. pneumoniae [PRSP] = 455/993), and H. influenzae ( N = 3850; BB- lactamase [ BBL]-negative = 3097; BBL-positive = 753) isolates were collected from respiratory tract speci-mens. Susceptibility to ceftaroline was 89.08%-97.83% for S. aureus, 99.95%-100% for MSSA, and 78.07%- 92.74% for MRSA isolates across age groups; S. aureus as well as MRSA isolates derived from the 0-18 years age group demonstrated the highest susceptibility rates to ceftaroline. Susceptibility to ceftaro-line was 98.25%-99.77% for S. pneumoniae, 99.74%-10 0% for PISP, and 86.23%-99.04% for PRSP isolates across age groups. Across all age groups, susceptibility to ceftaroline was 89.53%-99.70% for H. influenzae, 93.02%-10 0% for BBL-negative, and 77.78%-98.35% for BBL-positive isolates.Conclusion: Irrespective of age, susceptibility to ceftaroline was high among the majority of S. aureus, S. pneumoniae, and H. influenzae isolates collected in this study. & COPY; 2023 The Pfizer Inc and The Author(s). Published by Elsevier Ltd. On behalf of International Society for Chemotherapy of Infection and Cancer. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
